Abstract
Objective
Implantable cardioverter defibrillators (ICD) are successfully used to treat life-threatening arrhythmias and prevent sudden cardiac death. However, they are also known to have a major psychological impact leading to higher prevalence of depression and anxiety in a substantial proportion of patients. The aim of this study was to assess the prevalence of depressive symptoms in a large cohort of ICD carriers with a different clinical background and to compare prevalence and risk factors between patients with primary and secondary prophylactic indication for ICD implantation.
Methods
315 out of 622 patients (50.6%), who regularly attended ICD assessments at the University Hospital Zurich completed the Beck Depression Inventory (BDI I–II) to estimate current depressive symptoms.
Results
Overall, depressive symptoms were common in ICD patients, with 20.3% of the patients showing clinically relevant depression (12.4% mild depressive symptoms, 6.0% moderate, 1.9% severe). Moderate to severe depressive symptoms seem to be more likely in patients with secondary prophylactic indication of the ICD as compared to a group of patients with primary prophylactic implantation. Patients that received more than 5 ICD shocks since implantation reveal more depressive symptoms than those with less events. Mean BDI Score in total (n = 315) was at 8.44 ± 7.56 without a statistically significant difference between the primary (M = 8.04 ± 7.10, n = 153) and secondary (M = 8.81 ± 7.98, n = 162) preventive group (p value = 0.362), even after adjustment for various clinical characteristics. ICD patients should therefore be well supported and advised concerning the psychological impact of their device and particular aspects of daily life concerns (e.g. physical activity), with a special focus on patients, who have received multiple shocks.
Graphic abstract
Similar content being viewed by others
References
Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM et al (2011) Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 58(12):1254–1261
Maron BJ (2003) Sudden death in young athletes. N Engl J Med 349(11):1064–1075
Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P et al (2018) Outcomes of cardiac screening in adolescent soccer players. N Engl J Med 379(6):524–534
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al (2016) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. G Ital Cardiol 17(2):108-170
Myerburg RJ, Kessler KM, Castellanos A (1992) Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 85(1 Suppl):I2-10
Wellens HJ, Schwartz PJ, Lindemans FW, Buxton AE, Goldberger JJ, Hohnloser SH et al (2014) Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J 35(25):1642–1651
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635–1701
Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F et al (2009) Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 120(22):2170–2176
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al (2005) Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 352(3):225–237
van der Heijden AC, Borleffs CJ, Buiten MS, Thijssen J, van Rees JB, Cannegieter SC et al (2015) The clinical course of patients with implantable cardioverter–defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm 12(6):1169–1176
Oshvandi K, Khatiban M, Ghanei Gheshlagh R, Razavi M (2020) The prevalence of depression in patients living with implantable cardioverter defibrillator: a systematic review and meta-analysis. Ir J Med Sci 189(4):1243–1252
Magyar-Russell G, Thombs BD, Cai JX, Baveja T, Kuhl EA, Singh PP et al (2011) The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res 71(4):223–231
Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR et al (2002) Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105(5):589–594
Moshkani Farahani M, Taghipour M, Motalebi M, Bakhshian R, Shahverdi E, Taghipour S et al (2016) Depression and associated factors in patients with implantable cardioverter-defibrillators. J Tehran Heart Cent 11(4):168–173
Wong MF (2017) Factors associated with anxiety and depression among patients with implantable cardioverter defibrillator. J Clin Nurs 26(9–10):1328–1337
Smarr KL, Keefer AL (2011) Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken). 63(Suppl 11):S454–S466
Hoogwegt MT, Kupper N, Theuns DA, Zijlstra WP, Jordaens L, Pedersen SS (2012) Undertreatment of anxiety and depression in patients with an implantable cardioverter–defibrillator: impact on health status. Health Psychol 31(6):745–753
Weiss M, Michels G, Eberhardt F, Fehske W, Winter S, Baer F et al (2019) Anxiety, depression and quality of life in acute high risk cardiac disease patients eligible for wearable cardioverter defibrillator: Results from the prospective multicenter CRED-registry. PLoS ONE 14(3):e0213261
Whang W, Albert CM, Sears SF, Lampert R, Conti JB, Wang PJ et al (2005) Depression as a predictor for appropriate shocks among patients with implantable cardioverter–defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol 45(7):1090–1095
Veerman JL, Dowrick C, Ayuso-Mateos JL, Dunn G, Barendregt JJ (2009) Population prevalence of depression and mean Beck Depression Inventory score. Br J Psychiatry 195(6):516–519
Altman DG, Bland JM (2009) Parametric and non-parametric methods for data analysis. BMJ 338:a3167
Roelofs J (2013) Norms for the Beck Depression Inventory (BDI-II) in a Large Dutch Community Sample. J Psychopathol Behav Assess 35(1): 93-98
Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S et al (2019) Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 40(1):19–33
Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M et al (2013) Safety of sports for athletes with implantable cardioverter–defibrillators: results of a prospective, multinational registry. Circulation 127(20):2021–2030
Amiaz R, Asher E, Rozen G, Czerniak E, Levi L, Weiser M et al (2017) Reduction in depressive symptoms in primary prevention ICD scheduled patients—one year prospective study. Gen Hosp Psychiatry 48:37–41
Maroto-Montero JM, Maroto-de Pablo M, Starling-Duarte J, Prados-Cabiedas C, Villahoz-Garcia C, Cabrero-Soblechero L et al (2018) Sexual activity in implantable cardioverter defibrillator patients included in cardiac rehabilitation. Arch Cardiol Mex 88(2):116–123
Savastano S, Baldi E, Brondino N (2020) Psychiatric aspects of sudden cardiac arrest and implantable cardioverter-defibrillators. In: Govoni S, Politi P, Vanoli E (eds) Brain and heart dynamics. Springer International Publishing, Cham, pp 377–385
Brush JE, Handberg EM, Biga C, Birtcher KK, Bove AA, Casale PN et al (2015) 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol 65(19):2118–2136
Kovacs RJ, Drozda JP (2015) The changing face of team care, and a challenge for the future. J Am Coll Cardiol 65(19):2137–2139
Morgan JF, O’Donoghue AC, McKenna WJ, Schmidt MM (2008) Psychiatric disorders in hypertrophic cardiomyopathy. Gen Hosp Psychiatry 30(1):49–54
Hendriks KS, Hendriks MM, Birnie E, Grosfeld FJ, Wilde AA, van den Bout J et al (2008) Familial disease with a risk of sudden death: a longitudinal study of the psychological consequences of predictive testing for long QT syndrome. Heart Rhythm 5(5):719–724
Hintsa T, Keltikangas-Järvinen L, Puttonen S, Ravaja N, Toivonen L, Kontula K et al (2009) Depressive symptoms in the congenital long QT syndrome. Ann Med 41(7):516–521
Hintsa T, Jokela M, Elovainio M, Määttänen I, Swan H, Hintsanen M et al (2016) Stressful life events and depressive symptoms among symptomatic long QT syndrome patients. J Health Psychol 21(4):505–512
Watkins LL, Blumenthal JA, Davidson JR, Babyak MA, McCants CB, Sketch MH (2006) Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. Psychosom Med 68(5):651–656
Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA et al (2018) QT Prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics 59(2):105–122
Tripp C, Huber NL, Kuhl EA, Sears SF (2019) Measuring ICD shock anxiety: status update on the Florida Shock Anxiety Scale after over a decade of use. Pacing Clin Electrophysiol 42(10):1294–1301
Acknowledgements
The authors gratefully acknowledge the assistance of all participants. This study was performed by the Department of Cardiology of the University Hospital Zurich and was not funded by external organization.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest statement
No conflict of interest declared.
Rights and permissions
About this article
Cite this article
Ensslin, C., Berg, J., Hermes-Laufer, J. et al. Depressive symptoms in patients after primary and secondary prophylactic ICD implantation. Clin Res Cardiol 111, 1210–1218 (2022). https://doi.org/10.1007/s00392-021-01940-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-021-01940-w